ProfileGDS4814 / ILMN_1852758
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 46% 36% 42% 22% 46% 15% 21% 36% 22% 37% 30% 23% 30% 32% 24% 9% 19% 28% 26% 15% 27% 22% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)49.387646
GSM780708Untreated after 4 days (C2_1)46.756636
GSM780709Untreated after 4 days (C3_1)48.118442
GSM780719Untreated after 4 days (C1_2)43.939222
GSM780720Untreated after 4 days (C2_2)49.340446
GSM780721Untreated after 4 days (C3_2)42.383815
GSM780710Trastuzumab treated after 4 days (T1_1)43.826421
GSM780711Trastuzumab treated after 4 days (T2_1)46.909136
GSM780712Trastuzumab treated after 4 days (T3_1)43.911522
GSM780722Trastuzumab treated after 4 days (T1_2)47.03537
GSM780723Trastuzumab treated after 4 days (T2_2)45.619330
GSM780724Trastuzumab treated after 4 days (T3_2)44.232823
GSM780713Pertuzumab treated after 4 days (P1_1)45.601630
GSM780714Pertuzumab treated after 4 days (P2_1)45.915532
GSM780715Pertuzumab treated after 4 days (P3_1)44.289324
GSM780725Pertuzumab treated after 4 days (P1_2)40.95479
GSM780726Pertuzumab treated after 4 days (P2_2)43.41519
GSM780727Pertuzumab treated after 4 days (P3_2)45.194628
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)44.797726
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)42.464215
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.001727
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)44.02222
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)40.72399